Sangamo strikes another brain-targeting AAV partnership, this time with Astellas
Sangamo has made another gene therapy deal to keep the lights on for a few more months, extending its funding by another three months until …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
